Dendreon Wraps Up $409M Deal
Dendreon (NASDAQ: DNDN), the Seattle based company developing a treatment to stimulate the immune system against prostate cancer, said today it has tacked on an additional $55.7 million through its stock offering, bringing the grand total of this financing to $409 million after expenses. The company sold 15 million shares earlier in the week, and raised the extra money when its underwriters exercised their options to buy 2.25 million shares at $24.75 apiece. Dendreon has now raised a total of $630 million this year to support the manufacturing and marketing of sipuleucel-T (Provenge), as it seeks FDA approval to market the first-of-its-kind immune booster in the U.S.
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.